Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Vision for Digital Health Transformation


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    3
ATC Name B/G Ingredients Dosage Form Price
B05BA10 OLIMEL N9E B Glucose solution - 27.5%, Amino acids solution - 14.2%, Lipid emulsion - 20%, Sodium - 70mmol/2l, Potassium - 60mmol/2l, Magnesium - 8mmol/2l, Calcium - 7mmol/2l, Phosphate - 30mmol/2l, Acetate - 107mmol/2l, Chloride - 90mmol/2l, Azote - 18g/2l Injectable emulsion 5,496,316 L.L
B05BC01 OSMITOL G Mannitol - 20g/100ml 20g/100ml Injectable solution 579,064 L.L
C02KX04 OPSUMIT B Macitentan - 10mg 10mg Tablet, film coated 201,006,231 L.L
C09AA01 ORBACE G Captopril - 25mg 25mg Tablet 522,179 L.L
C09AA01 ORBACE G Captopril - 50mg 50mg Tablet 949,649 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 20mg 20mg Tablet, film coated 888,280 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 20mg 20mg Tablet, film coated 667,890 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 920,532 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 40mg 40mg Tablet, film coated 721,643 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 25mg Tablet, film coated 653,107 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 40mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 653,107 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 25mg Tablet, film coated 628,918 L.L
C09DA08 OLMENOR PLUS G Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 628,918 L.L
C09DB02 OLMENOR COMBI G Olmesartan medoxomil - 20mg, Amlodipine - 5mg Tablet, film coated 679,984 L.L
C09DB02 OLMENOR COMBI G Olmesartan medoxomil - 40mg, Amlodipine - 5mg Tablet, film coated 772,709 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 10mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 10mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 20mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,037,446 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,067,011 L.L
C09DX03 OLMENOR TRIPLE G Olmesartan medoxomil - 40mg, Amlodipine (besylate) - 5mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 1,067,011 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 10mg 10mg Tablet 966,287 L.L
C10AA05 ORVASTA G Atorvastatin - 10mg 10mg Tablet, film coated 834,526 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 20mg 20mg Tablet 1,091,712 L.L
C10AA05 ORVASTA G Atorvastatin - 20mg 20mg Tablet, film coated 920,532 L.L
C10AA05 ORBALIP G Atorvastatin (calcium) - 40mg 40mg Tablet 1,405,275 L.L
C10AA05 ORVASTA G Atorvastatin - 40mg 40mg Tablet, film coated 1,170,487 L.L
C10BA05 OTOREZA G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 2,213,309 L.L
C10BA05 OTOREZA 10/10 G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 1,007,882 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025